Homer A. Macapinlac, M.D., FACNM

Peer-Reviewed Articles

1. Kairemo K, Gouda M, Chuang HH, Macapinlac HA, Subbiah V. Deciphering Tumor Response: The Role of Fluoro-18-d-Glucose Uptake in Evaluating Targeted Therapies with Tyrosine Kinase Inhibitors. J Clin Med 13(11), 2024. e-Pub 2024. PMID: 38892979.
2. Cherng HJ, Xu G, Feng L, Steiner R, Fayad L, Strati P, Nair R, Nastoupil LJ, Lee HJ, Neelapu SS, Flowers CR, Rodriguez M, Wang M, Hagemeister F, Pinnix CC, Ramdial J, Srour S, Nieto Y, Rezvani K, Champlin R, Kebriaei P, Westin J, Macapinlac HA, Shpall E, Ahmed S. Positron emission tomography derived metrics in relapsed or refractory large B-cell lymphoma with residual disease before autologous stem cell transplant. Br J Haematol 200(1):35-44, 2023. e-Pub 2022. PMID: 36068929.
3. Kairemo K, Kangasmäki A, Kappadath SC, Joensuu T, Macapinlac HA. A Retrospective Comparative Study of Sodium Fluoride Na18F-PET/CT and 68Ga-PSMA-11 PET/CT in the Bone Metastases of Prostate Cancer Using a Volumetric 3-D Radiomic Analysis. Life (Basel) 12(12), 2022. e-Pub 2022. PMID: 36556342.
4. Jimenez JE, Dai D, Xu G, Zhao R, Li T, Pan T, Wang L, Lin Y, Wang Z, Jaffray D, Hazle JD, Macapinlac HA, Wu J, Lu Y. Lesion-based radiomics signature in pretherapy 18F-FDG PET predicts treatment response to Ibrutinib in lymphoma. Clin Nucl Med 47(3):209-218, 2022. PMID: 35020640.
5. Yadav D, Hwang H, Qiao W, Upadhyay R, Chapin BF, Tang C, Aparicio A, Lopez-Olivo MA, Kang SK, Macapinlac HA, Bathala TK, Surasi DS. 18F-Fluciclovine versus PSMA PET Imaging in Primary Tumor Detection during Initial Staging of High-Risk Prostate Cancer: A Systematic Review and Meta-Analysis. Radiol Imaging Cancer 4(2):e210091, 2022. PMID: 35212559.
6. Cherng HJ, Chuang HH, Steiner R, Fayad L, Strati P, Nair R, Hagemeister F, Nastoupil LJ, Lee HJ, Neelapu SS, Flowers CR, Samaniego F, Rodriguez M, Macapinlac HA, Feng L, Westin J. A prospective study on early PET/CT scans during the first cycle of salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma. Leuk Lymphoma 63(1):1-10, 2022. e-Pub 2021. PMID: 34435552.
7. Lin M, Paolillo V, Le DB, Macapinlac HA, Ravizzini GC. Monoclonal antibody based radiopharmaceuticals for imaging and therapy. Curr Probl Cancer 45(5):100796, 2021. e-Pub 2021. PMID: 34657748.
8. Kairemo K, Roszik J, Anderson P, Ravizzini G, Rao A, Macapinlac HA, Subbiah V. 18F-sodium fluoride positron emission tomography (NaF-18-PET/CT) radiomic signatures to evaluate responses to alpha-particle Radium-223 dichloride therapy in osteosarcoma metastases. Curr Probl Cancer 45(5):100797, 2021. e-Pub 2021. PMID: 34706830.
9. Minamimoto R, Fayad L, Vose J, Meza J, Advani R, Hankins J, Mottaghy F, Macapinlac H, Heinzel A, Juweid ME, Quon A. 18F-Fluorothymidine PET is an early and superior predictor of progression-free survival following chemoimmunotherapy of diffuse large B cell lymphoma: a multicenter study. Eur J Nucl Med Mol Imaging 48(9):2883-2893, 2021. e-Pub 2021. PMID: 33909086.
10. Baiomy A, Schellingerhout D, Chapin BF, Weinberg JS, Raza SM, Macapinlac HA, Ravizzini G. Rate of incidental central nervous system meningioma detected in patients undergoing 18F-fluciclovine PET/CT imaging for evaluation of prostate cancer. Nucl Med Commun 42(7):755-762, 2021. e-Pub 2021. PMID: 33741867.
11. Teyateeti A, Teyateeti A, Ravizzini GC, Xu G, Tang C, Tu SM, Macapinlac HA, Lu Y. Diagnostic performance of 18F-fluciclovine PET/CT in prostate cancer patients with rising PSA level = 0.5 ng/ml after multiple treatment failures. Am J Nucl Med Mol Imaging 11(2):87-98, 2021. e-Pub 2021. PMID: 34079638.
12. Zhou Z, Jain P, Lu Y, Macapinlac H, Wang ML, Son JB, Pagel MD, Xu G, Ma J. Computer-aided detection of mantle cell lymphoma on 18F-FDG PET/CT using a deep learning convolutional neural network. Am J Nucl Med Mol Imaging 11(4):260-270, 2021. e-Pub 2021. PMID: 34513279.
13. Kairemo K, Kappadath SC, Joensuu T, Macapinlac HA. A Retrospective Comparative Study of Sodium Fluoride (NaF-18)-PET/CT and Fluorocholine (F-18-CH) PET/CT in the Evaluation of Skeletal Metastases in Metastatic Prostate Cancer Using a Volumetric 3-D Radiomics Analysis. Diagnostics (Basel) 11(1), 2020. e-Pub 2020. PMID: 33374148.
14. Subbiah V, Erwin W, Mawlawi O, McCoy A, Wages D, Wheeler C, Gonzalez-Lepera C, Liu H, Macapinlac HA, Meric-Bernstam F, Hong DS, Pant S, Le D, Santos E, Gonzalez J, Roszik J, Suzuki T, Subach RA, Madden T, Johansen M, Nomura F, Satoh H, Matsuura T, Kajita M, Nakamura E, Funase Y, Matsushima S, Ravizzini G. Phase 1 Study of P-cadherin-Targeted Radioimmunotherapy with 90Y-FF-21101 Monoclonal Antibody in Solid Tumors. Clin Cancer Res 26(22):5830-5842, 2020. e-Pub 2020. PMID: 32816889.
15. Teyateeti A, Macapinlac, HA, Lu Y. Is There Any Role for 18F-Fluciclovine PET/CT in the Presence of Undetectable PSA in Prostate Cancer Patients After Definitive Treatment?. Clin Nucl Med 45(9):672-678, 2020. PMID: 32604105.
16. Teyateeti A, Khan B, Chen B, Bridhikitti J, Pan T, Peng W, Macapinlac, HA, Lu Y. Diagnostic performance of F-18 fluciclovine PET/CT in post-radical prostatectomy prostate cancer patients with rising prostate-specific antigen level =0.5 ng/mL. Nucl Med Commun 41(9):906-915, 2020. PMID: 32796479.
17. Lu Y, Macapinlac HA. Perfusion SPECT/CT to diagnose pulmonary embolism during COVID-19 pandemic. Eur J Nucl Med Mol Imaging 47(9):2064-2065, 2020. e-Pub 2020. PMID: 32383092.
18. Lu Y, Yan SX, Lan X, Zhu X, Macapinlac HA. Nuclear medicine in responding to global pandemic COVID-19-American College of Nuclear Medicine member experience. Eur J Nucl Med Mol Imaging 47(7):1620-1622, 2020. PMID: 32296884.
19. Chen B, Bathala TK, Xu G, Teyateeti A, Chapin BF, Tang C, Tu SM, Macapinlac, HA, Lu Y. Comparison of Diagnostic Utility of Fluciclovine PET/CT Versus Pelvic Multiparametric MRI for Prostate Cancer in the Pelvis in the Setting of Rising PSA After Initial Treatment. Clin Nucl Med 45(5):349-355, 2020. e-Pub 2020. PMID: 31977495.
20. Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, Nassif Kerbauy L, Overman B, Thall P, Kaplan M, Nandivada V, Kaur I, Nunez Cortes A, Cao K, Daher M, Hosing C, Cohen EN, Kebriaei P, Mehta R, Neelapu S, Nieto Y, Wang M, Wierda W, Keating M, Champlin R, Shpall EJ, Rezvani K. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. N Engl J Med 382(6):545-553, 2020. PMID: 32023374.
21. Kairemo K, Santos EB, Macapinlac HA, Patel S, Conley AP, Hong DS, Subbiah AV. Molecular Imaging with 3'-deoxy-3'[(18)F]-Fluorothymidine (18F-FLT) PET/CT for Early Response to Targeted Therapies in Sarcomas: A Pilot Study. Diagnostics (Basel) 10(3), 2020. e-Pub 2020. PMID: 32106426.
22. Kairemo K, Santos EB, Macapinlac HA, Subbiah V. Early Response Assessment to Targeted Therapy Using 3'-deoxy-3'[(18)F]-Fluorothymidine (18F-FLT) PET/CT in Lung Cancer. Diagnostics (Basel) 10(1), 2020. e-Pub 2020. PMID: 31935818.
23. Teyateeti A, Mahvash A, Long JP, Abdelsalam ME, Avritscher R, Chasen B, Kaseb AO, Kuban JD, Murthy R, Odisio BC, Teyateeti A, Macapinlac HA, Kappadath SC. Survival Outcomes for Yttrium-90 Transarterial Radioembolization With and Without Sorafenib for Unresectable Hepatocellular Carcinoma Patients. J Hepatocell Carcinoma 7:117-131, 2020. e-Pub 2020. PMID: 32984089.
24. Chen B, Wei P, Macapinlac, HA, Lu Y. Comparison of 18F-Fluciclovine PET/CT and 99mTc-MDP bone scan in detection of bone metastasis in prostate cancer. Nucl Med Commun 40(9):940-946, 2019. PMID: 31343613.
25. Subbiah V, Anderson PM, Kairemo K, Hess K, Huh WW, Ravi V, Daw NC, Somaiah N, Ludwig JA, Benjamin RS, Chawla S, Hong DS, Meric-Bernstam F, Ravizzini G, Kleinerman E, Macapinlac, HA, Rohren E. Alpha particle Radium 223 dichloride in high-risk osteosarcoma: a phase I dose escalation trial. Clin Cancer Res 25(13):3802-3810, 2019. e-Pub 2019. PMID: 30733229.
26. Kairemo K, Rohren EM, Anderson PM, Ravizzini G, Rao A, Macapinlac HA, Subbiah V. Development of sodium fluoride PET response criteria for solid tumours (NAFCIST) in a clinical trial of radium-223 in osteosarcoma: from RECIST to PERCIST to NAFCIST. ESMO Open 4(1):e000439, 2019. e-Pub 2019. PMID: 30962954.
27. Rohren EM, Etchebehere EC, Araujo JC, Hobbs BP, Swanston NM, Everding M, Moody T, Macapinlac HA. DETERMINATION OF SKELETAL TUMOR BURDEN ON 18F-FLUORIDE PET/CT. J Nucl Med 56(10):1507-12, 2015. e-Pub 2015. PMID: 26135112.
28. Etchebehere EC, Araujo JC, Fox PS, Swanston NM, Macapinlac HA, Rohren EM. Prognostic factors in patients treated with radium-223: the role of skeletal tumor burden on baseline 18F-fluoride-PET/CT in predicting overall survival. J Nucl Med 56(8):1177-84, 2015. e-Pub 2015. PMID: 26069307.
29. Machtay M, Duan F, Siegel BA, Snyder BS, Gorelick JJ, Reddin JS, Munden R, Johnson DW, Wilf LH, DeNittis A, Sherwin N, Cho KH, Kim SK, Videtic G, Neumann DR, Komaki R, Macapinlac HA, Bradley JD, Alavi A. Prediction of Survival by [18F]Fluorodeoxyglucose Positron Emission Tomography in Patients With Locally Advanced Non-Small-Cell Lung Cancer Undergoing Definitive Chemoradiation Therapy: Results of the ACRIN 6668/RTOG 0235 Trial. J Clin Oncol 31(30):3823-30, 2013. e-Pub 2013. PMID: 24043740.
30. Frumovitz M, Querleu D, Gil-Moreno A, Morice P, Jhingran A, Munsell MF, Macapinlac HA, Leblanc E, Martinez A, Ramirez PT. Lymphadenectomy in Locally Advanced Cervical Cancer Study (LiLACS): A phase III clinical trial comparing surgical to radiologic staging in patients with stages IB2-IVA cervical cancer. J Minim Invasive Gynecol. e-Pub 2013. PMID: 23911560.
31. Tateishi U, Terauchi T, Akashi-Tanaka S, Kinoshita T, Kano D, Daisaki H, Murano T, Tsuda H, Macapinlac HA. A comparative study on the value of dual tracer PET/CT to evaluate breast cancer. (18) F-FDG PET/CT images reveal a focal hypermetabolic focus of the primary tumor (upper panel), whereas (11) C-choline PET/CT images reveal only a focal hypermetabolic focus in the primary tumor (lower panel). Cancer Sci 103(9):Septembercover, 2012. PMID: 22938535.
32. Erasmus JJ, Macapinlac HA. Low-sensitivity FDG-PET studies: less common lung neoplasms. Semin Nucl Med 42(4):255-60, 2012. PMID: 22681674.
33. Frumovitz M, Ramirez PT, Macapinlac HA, Klopp AH, Nick AM, Ramondetta LM, Jhingran A. Anatomic Location of PET-Positive Aortocaval Nodes in Patients with Locally Advanced Cervical Cancer: Implications for Surgical Staging. Int J Gynecol Cancer. e-Pub 2012. PMID: 22810967.
34. Ajani JA, Correa AM, Hofstetter WL, Rice DC, Blum MA, Suzuki A, Taketa T, Welsh J, Lin SH, Lee JH, Bhutani MS, Ross WA, Maru DM, Macapinlac HA, Erasmus J, Komaki R, Mehran RJ, Vaporciyan AA, Swisher SG. Clinical parameters model for predicting pathologic complete response following preoperative chemoradiation in patients with esophageal cancer. Ann Oncol. e-Pub 2012. PMID: 22831985.
35. Younes A, Oki Y, McLaughlin P, Copeland AR, Goy A, Pro B, Feng L, Yuan Y, Chuang HH, Macapinlac HA, Hagemeister F, Romaguera J, Samaniego F, Fanale MA, Dabaja BS, Rodriguez MA, Dang N, Kwak LW, Neelapu SS, Fayad LE. Phase II study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. Blood 119(18):4123-8, 2012. e-Pub 2012. PMID: 22371887.
36. Khouri IF, Saliba RM, Erwin WD, Samuels BI, Korbling M, Medeiros LJ, Valverde R, Alousi AM, Anderlini P, Bashir Q, Ciurea S, Gulbis AM, de Lima M, Hosing C, Kebriaei P, Popat UR, Fowler N, Neelapu SS, Samaniego F, Champlin RE, Macapinlac HA. Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results. Blood. e-Pub 2012. PMID: 22586182.
37. Tateishi U, Terauchi T, Akashi-Tanaka S, Kinoshita T, Kano D, Daisaki H, Murano T, Tsuda H, Macapinlac HA. A Comparative Study on the Value of Dual Tracer PET/CT to Evaluate Breast Cancer. Cancer Sci. e-Pub 2012. PMID: 22632272.
38. Tateishi U, Miyake M, Nagaoka T, Terauchi T, Kubota K, Kinoshita T, Daisaki H, Macapinlac HA. Neoadjuvant Chemotherapy in Breast Cancer: Prediction of Pathologic Response with PET/CT and Dynamic Contrast-enhanced MR Imaging--Prospective Assessment. Radiology 263(1):53-63, 2012. PMID: 22438441.
39. Suzuki A, Xiao L, Hayashi Y, Macapinlac HA, Welsh J, Lin SH, Lee JH, Bhutani MS, Maru DM, Hofstetter WL, Swisher SG, Ajani JA. Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with esophageal or gastroesophageal junction cancer treated with definitive chemoradiotherapy. Cancer 117(21):4823-33, 2011. e-Pub 2011. PMID: 21456015.
40. Jackson J, Pan T, Tonkopi E, Swanston N, Macapinlac HA, Rohren EM. Implementation of Automated Tube Current Modulation in PET/CT: Prospective Selection of a Noise Index and Retrospective Patient Analysis to Ensure Image Quality. J Nucl Med Technol 39(2):83-90, 2011. e-Pub 2011. PMID: 21565950.
41. Ramirez PT, Jhingran A, Macapinlac HA, Euscher ED, Munsell MF, Coleman RL, Soliman PT, Schmeler KM, Frumovitz M, Ramondetta LM. Laparoscopic extraperitoneal para-aortic lymphadenectomy in locally advanced cervical cancer1: a prospective correlation of surgical findings with positron emission tomography/computed tomography findings. Cancer 117(9):1928-34, 2011. e-Pub 2010. PMID: 21509770.
42. Leibold T, Akhurst TJ, Chessin DB, Yeung HW, Macapinlac HA, Shia J, Minsky BD, Saltz LB, Riedel E, Mazumdar M, Paty PB, Weiser MR, Wong WD, Larson SM, Guillem JG. Evaluation of (18)F-FDG-PET for Early Detection of Suboptimal Response of Rectal Cancer to Preoperative Chemoradiotherapy: A Prospective Analysis. Ann Surg Oncol. e-Pub 2011. PMID: 21476107.
43. Dickinson RL, Erwin WD, Stevens DM, Bidaut LM, Mar MV, Macapinlac HA, Wendt RE. Hybrid Modality Fusion of Planar Scintigrams and CT Topograms to Localize Sentinel Lymph Nodes in Breast Lymphoscintigraphy: Technical Description and Phantom Studies. Int J Mol Imaging 2011:298102, 2011. e-Pub 2010. PMID: 21490727.
44. Moeller BJ, Rana V, Cannon BA, Williams MD, Sturgis EM, Ginsberg LE, Macapinlac HA, Lee JJ, Ang KK, Chao KS, Chronowski GM, Frank SJ, Morrison WH, Rosenthal DI, Weber RS, Garden AS, Lippman SM, Schwartz DL. Prospective Imaging Assessment of Mortality Risk After Head-and-Neck Radiotherapy. Int J Radiat Oncol Biol Phys 78(3):667-74, 2010. e-Pub 2010. PMID: 20171802.
45. Ramirez PT, Jhingran A, Macapinlac HA, Euscher ED, Munsell MF, Coleman RL, Soliman PT, Schmeler KM, Frumovitz M, Ramondetta LM. Laparoscopic extraperitoneal para-aortic lymphadenectomy in locally advanced cervical cancer1: a prospective correlation of surgical findings with positron emission tomography/computed tomography findings. Cancer. e-Pub 2010. PMID: 21082702.
46. Patnana SV, Murthy SB, Xiao L, Rohren E, Hofstetter WL, Swisher SG, Liao Z, Lee JH, Bhutani MS, Macapinlac HA, Wang X, Ajani JA. Critical role of surgery in patients with gastroesophageal carcinoma with a poor prognosis after chemoradiation as defined by positron emission tomography. Cancer 116(19):4487-94, 2010. e-Pub 2010. PMID: 20629031.
47. Kröger N, Bacher U, Bader P, Böttcher S, Borowitz MJ, Dreger P, Khouri I, Macapinlac HA, Olavarria E, Radich J, Stock W, Vose JM, Weisdorf D, Willasch A, Giralt S, Bishop MR, Wayne AS. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, acute leukemias, and myelodysplastic syndromes. Biol Blood Marrow Transplant 16(9):1187-211, 2010. e-Pub 2010. PMID: 20558311.
48. Kim MP, Correa AM, Lee J, Rice DC, Roth JA, Mehran RJ, Walsh GL, Ajani JA, Maru DM, Chang JY, Marom EM, Macapinlac HA, Lee JH, Vaporciyan AA, Rice T, Swisher SG, Hofstetter WL. Pathologic T0N1 esophageal cancer after neoadjuvant therapy and surgery: an orphan status. Ann Thorac Surg 90(3):884-90; discussion 890-1, 2010. PMID: 20732513.
49. De Giorgi U, Mego M, Rohren EM, Liu P, Handy BC, Reuben JM, Macapinlac HA, Hortobagyi GN, Cristofanilli M, Ueno NT. 18F-FDG PET/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases from breast cancer. J Nucl Med 51(8):1213-8, 2010. e-Pub 2010. PMID: 20660382.
50. Bhosale P, Peungjesada S, Wei W, Levenback CF, Schmeler K, Rohren E, Macapinlac HA, Iyer RB. Clinical utility of positron emission tomography/computed tomography in the evaluation of suspected recurrent ovarian cancer in the setting of normal CA-125 levels. Int J Gynecol Cancer 20(6):936-44, 2010. PMID: 20683399.
51. Murthy SB, Patnana SV, Xiao L, Rohren E, Hofstetter WL, Swisher SG, Liao Z, Lee JH, Bhutani MS, Macapinlac HA, Wang X, Ajani JA. The Standardized Uptake Value of 18-Fluorodeoxyglucose Positron Emission Tomography after Chemoradiation and Clinical Outcome in Patients with Localized Gastroesophageal Carcinoma. Oncology 78(5-6):316-322. e-Pub 2010. PMID: 20699623.
52. Kei PL, Vikram R, Yeung HW, Stroehlein JR, Macapinlac HA. Incidental finding of focal FDG uptake in the bowel during PET/CT: CT features and correlation with histopathologic results. AJR Am J Roentgenol 194(5):W401-6, 2010. PMID: 20410385.
53. Núñez R, Erwin WD, Wendt RE, Stachowiak A, Mar M, Stevens D, Madewell JE, Yeung HW, Macapinlac HA. Acquisition Parameters for Oncologic Imaging with a New SPECT/Multislice CT Scanner. Mol Imaging Biol 12(2):110-38, 2010. PMID: 20049543.
54. De Giorgi U, Valero V, Rohren E, Mego M, Doyle GV, Miller MC, Ueno NT, Handy BC, Reuben JM, Macapinlac HA, Hortobagyi GN, Cristofanilli M. Circulating tumor cells and bone metastases as detected by FDG-PET/CT in patients with metastatic breast cancer. Ann Oncol 21(1):33-9, 2010. PMID: 19602564.
55. Tonkopi E, Chi PC, Mawlawi O, Riegel AC, Rohren EM, Macapinlac HA, Pan T. Average CT in PET studies of colorectal cancer patients with metastasis in the liver and esophageal cancer patients. J Appl Clin Med Phys 11(1):3073, 2010. PMID: 20160693.
56. Macapinlac HA, Czernin J, Larson SM. Practice Based Evidence of the Beneficial Impact of PET in Patients with Brain Tumors. Mol Imaging Biol 13(1):1-2, 2010. e-Pub 2010. PMID: 21082268.
57. Javeri H, Xiao L, Rohren E, Lee JH, Liao Z, Hofstetter W, Maru D, Bhutani MS, Swisher SG, Macapinlac HA, Wang X, Ajani JA. The higher the decrease in the standardized uptake value of positron emission tomography after chemoradiation, the better the survival of patients with gastroesophageal adenocarcinoma. Cancer 115(22):5184-92, 2009. PMID: 19685531.
58. Schechter NR, Erwin WD, Yang DJ, Kim EE, Munden RF, Forster K, Taing LC, Cox JD, Macapinlac HA, Podoloff DA. Radiation dosimetry and biodistribution of (99m)Tc-ethylene dicysteine-deoxyglucose in patients with non-small-cell lung cancer. Eur J Nucl Med Mol Imaging 36(10):1583-91, 2009. PMID: 19396440.
59. Chuang HH, Macapinlac HA. The evolving role of PET-CT in the management of esophageal cancer. Q J Nucl Med Mol Imaging 53(2):201-9, 2009. PMID: 19293768.
60. Podoloff DA, Ball DW, Ben-Josef E, Benson AB, Cohen SJ, Coleman RE, Delbeke D, Ho M, Ilson DH, Kalemkerian GP, Lee RJ, Loeffler JS, Macapinlac HA, Morgan RJ, Siegel BA, Singhal S, Tyler DS, Wong RJ. NCCN task force: clinical utility of PET in a variety of tumor types. J Natl Compr Canc Netw 7 Suppl 2:S1-26, 2009. PMID: 19555588.
61. De Giorgi U, Valero V, Rohren E; Shaheenah D, Ueno NT, Miller MC, Doyle GV, Jackson S, Andreopoulou E, Handy BC, Reuben JM, Fritsche Jr HA, Macapinlac HA, Hortobagyi GN, Cristofanilli M. Circulating Tumor Cells and [18F]Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Outcome Prediction in Metastatic Breast Cancer. J Clin Oncol 27(20):3303-11, 2009. PMID: 19451443.
62. Moeller BJ, Rana V, Cannon BA, Williams MD, Sturgis EM, Ginsberg LE, Macapinlac HA, Lee JJ, Ang KK, Chao KS, Chronowski GM, Frank SJ, Morrison WH, Rosenthal DI, Weber RS, Garden AS, Lippman SM, Schwartz DL. Prospective Risk-Adjusted [18F]Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography Assessment of Radiation Response in Head and Neck Cancer. J Clin Oncol 27(15):2509-15, 2009. PMID: 19332725.
63. Macapinlac HA, Segall G. Continuously Improving PET Utilization. J Nucl Med 50(5):22N-5N, 2009. PMID: 19403875.
64. Costelloe CM, Macapinlac HA, Madewell JE, Fitzgerald NE, Mawlawi OR, Rohren EM, Raymond AK, Lewis VO, Anderson PM, Bassett RL, Harrell RK, Marom EM. 18F-FDG PET/CT as an indicator of progression-free and overall survival in osteosarcoma. J Nucl Med 50(3):340-7, 2009. PMID: 19258257.
65. Carkaci S, Macapinlac HA, Cristofanilli M, Mawlawi O, Rohren E, Gonzalez Angulo AM, Dawood S, Resetkova E, Le-Petross HT, Yang WT. Retrospective Study of 18F-FDG PET/CT in the Diagnosis of Inflammatory Breast Cancer: Preliminary Data. J Nucl Med 50(2):231-8, 2009. e-Pub 2009. PMID: 19164229.
66. Tateishi U, Gamez C, Dawood S, Yeung HW, Cristofanilli M, Inoue T, Macapinlac HA. Chronic thyroiditis in patients with advanced breast carcinoma: metabolic and morphologic changes on PET-CT. Eur J Nucl Med Mol Imaging 36(6):894-902, 2009. PMID: 19156410.
67. Vikram R, Yeung HD, Macapinlac HA, Iyer RB. Utility of PET/CT in differentiating benign from malignant adrenal nodules in patients with cancer. AJR Am J Roentgenol 191(5):1545-51, 2008. PMID: 18941099.
68. Macapinlac HA, Segall G. Building a Foundation for Better PET Utilization. J Nucl Med 49(9):46N-56N, 2008. PMID: 18765584.
69. Chi PC, Mawlawi O, Luo D, Liao Z, Macapinlac HA, Pan T. Effects of respiration-averaged computed tomography on positron emission tomography/computed tomography quantification and its potential impact on gross tumor volume delineation. Int J Radiat Oncol Biol Phys 71(3):890-9, 2008. PMID: 18514781.
70. Reed VK, Cavalcanti JL, Strom EA, Perkins GH, Oh JL, Tereffe W, Yu TK, Yeung H, Whitman GJ, Bedrosian I, Macapinlac HA, Buchholz TA, Woodward WA. Risk of Subclinical Micrometastatic Disease in the Supraclavicular Nodal Bed According to the Anatomic Distribution in Patients with Advanced Breast Cancer. Int J Radiat Oncol Biol Phys 71(2):435-40, 2008. e-Pub 2007. PMID: 18164831.
71. Alousi AM, Saliba RM, Okoroji GJ, Macapinlac HA, Hosing C, Korbling M, Samuels BI, Popat U, Kebriaei P, Anderlini P, Qazilbash MH, de Lima M, Giralt SA, Champlin RE, Khouri IF. Disease staging with positron emission tomography or gallium scanning and use of rituximab predict outcome for patients with diffuse large B-cell lymphoma treated with autologous stem cell transplantation. Br J Haematol 142(5):786-92, 2008. e-Pub 2008. PMID: 18564354.
72. Schwartz DL, Macapinlac HA, Weber RS. FDG-PET staging of head and neck cancer--can improved imaging lead to improved treatment?. J Natl Cancer Inst 100(10):688-9, 2008. e-Pub 2008. PMID: 18477798.
73. Anderlini P, Swanston N, Rashid A, Bueso-Ramos C, Macapinlac HA, Champlin RE. Evidence of a graft-versus-Hodgkin lymphoma effect in the setting of extensive bone marrow involvement. Biol Blood Marrow Transplant 14(4):478-80, 2008. PMID: 18342791.
74. Tateishi U, Gamez C, Dawood S, Yeung HW, Cristofanilli M, Macapinlac HA. Bone metastases in patients with metastatic breast cancer: morphologic and metabolic monitoring of response to systemic therapy with integrated PET/CT. Radiology 247(1):189-96, 2008. PMID: 18372468.
75. Kazama T, Faria SC, Uchida Y, Ito H, Macapinlac HA. Pulmonary drug toxicity: FDG-PET findings in patients with lymphoma. Ann Nucl Med 22(2):111-4, 2008. PMID: 18311535.
76. Macapinlac HA. Clinical applications of positron emission tomography/computed tomography treatment planning. Semin Nucl Med 38(2):137-40, 2008. PMID: 18243849.
77. Chamilos G, Macapinlac HA, Kontoyiannis DP. The use of 18F-fluorodeoxyglucose positron emission tomography for the diagnosis and management of invasive mould infections. Med Mycol 46(1):23-9, 2008. PMID: 18297544.
78. Yang WT, Le-Petross HT, Macapinlac HA, Carkaci S, Gonzalez-Angulo AM, Dawood S, Resetkova E, Hortobagyi GN, Cristofanilli M. Inflammatory breast cancer: PET/CT, MRI, mammography and sonography findings. Breast Cancer Res Treat 109(3):417-26, 2008. PMID: 17653852.
79. Yang WT, Lane DL, Le-Petross HT, Abruzzo LV, Macapinlac HA. Breast lymphoma: imaging findings of 32 tumors in 27 patients. Radiology 245(3):692-702, 2007. e-Pub 2007. PMID: 17911538.
80. Klopp AH, Chang JY, Tucker SL, Sulman EP, Balter PA, Liu HH, Bucci MK, Macapinlac HA, Komaki R, Cox JD. Intrathoracic patterns of failure for non-small-cell lung cancer with positron-emission tomography/computed tomography-defined target delineation. Int J Radiat Oncol Biol Phys 69(5):1409-16, 2007. e-Pub 2007. PMID: 17904303.
81. Bruzzi JF, Munden RF, Truong MT, Marom EM, Sabloff BS, Gladish GW, Iyer RB, Pan TS, Macapinlac HA, Erasmus JJ. PET/CT of esophageal cancer: its role in clinical management. Radiographics 27(6):1635-52, 2007. PMID: 18025508.
82. Erasmus JJ, Macapinlac HA, Swisher SG. Positron emission tomography imaging in nonsmall-cell lung cancer. Cancer 110(10):2155-68, 2007. PMID: 17896784.
83. Cavalcanti JL, Núñez RF, Yeung HW, Mehran RJ, Macapinlac HA. Incidental finding of prostate cancer and adenomatous colon polyp in a patient with lung cancer. Clin Nucl Med 32(11):871-3, 2007. PMID: 18075426.
84. Namwongprom S, Núñez RF, Yeung HW, Kim EE, Macapinlac HA. Unusual adrenal metastasis and abdominal carcinomatosis secondary to Hurthle cell carcinoma of the thyroid. Exp Clin Endocrinol Diabetes 115(10):694-6, 2007. PMID: 18058606.
85. Podoloff DA, Macapinlac HA. PET and PET/CT in Management of the Lymphomas. Radiol Clin North Am 45(4):689-96, vii, 2007. PMID: 17706533.
86. Núñez R, Yeung HW, Swanston NM, Macapinlac HA. FDG uptake in gall bladder in the PET and PET/CT scan of three oncology patients. Rev Esp Med Nucl 26(4):234-6, 2007. PMID: 17662192.
87. Mar MV, Miller SA, Kim EE, Macapinlac HA. Evaluation and localization of lymphatic drainage and sentinel lymph nodes in patients with head and neck melanomas by hybrid SPECT/CT lymphoscintigraphic imaging. J Nucl Med Technol 35(1):10-6; quiz 17-20, 2007. PMID: 17337652.
88. Won KS, Gayed I, Kim EE, Macapinlac HA. Juvenile fibroadenoma of the breast demonstrated on (111)In-octreotide SPECT and (18)F-FDG PET/CT. Eur J Nucl Med Mol Imaging 34(3):440, 2007. e-Pub 2006. PMID: 17119960.
89. Benjamin RS, Choi H, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA, Charnsangavej C. We should desist using RECIST, at least in GIST. J Clin Oncol 25(13):1760-4, 2007. PMID: 17470866.
90. Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA, Benjamin RS. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 1;25(13):1753-9, 2007. PMID: 17470865.
91. Namwongprom S, Núñez R, Kim EE, Macapinlac HA. Tc-99m MDP bone scintigraphy and positron emission tomography/computed tomography (PET/CT) imaging in Erdheim-Chester disease. Clin Nucl Med 32(1):35-8, 2007. PMID: 17179801.
92. Bruzzi JF, Swisher SG, Truong MT, Munden RF, Hofstetter WL, Macapinlac HA, Correa AM, Mawlawi O, Ajani JA, Komaki RR, Fukami N, Erasmus JJ. Detection of interval distant metastases: clinical utility of integrated CT-PET imaging in patients with esophageal carcinoma after neoadjuvant therapy. Cancer 109(1):125-34, 2007. PMID: 17146785.
93. Iyer RB, Balachandran A, Bruzzi JF, Johnson V, Macapinlac HA, Munden RF. PET/CT and hepatic radiation injury in esophageal cancer patients. Cancer Imaging 7:189-94, 2007. PMID: 18055293.
94. Bruzzi JF, Truong MT, Macapinlac HA, Munden RF, Erasmus JJ. Integrated CT-PET imaging of esophageal cancer: unexpected and unusual distribution of distant organ metastases. Curr Probl Diagn Radiol 36(1):21-9, 2007. PMID: 17198889.
95. Bruzzi JF, Truong MT, Marom EM, Mawlawi O, Podoloff DA, Macapinlac HA, Munden RF. Incidental findings on integrated PET/CT that do not accumulate 18F-FDG. AJR Am J Roentgenol 187(4):1116-23, 2006. PMID: 16985164.
96. Munden RF, Truong MT, Gladish GW, Podoloff DA, Mawlawi O, Broemeling LD, Bruzzi JF, Macapinlac HA. Interobserver and intraobserver variability of standardized uptake value measurements in non-small-cell lung cancer. J Thorac Imaging 21(3):205-12, 2006. PMID: 16915065.
97. Erasmus JJ, Munden RF, Truong MT, Ho JJ, Hofstetter WL, Macapinlac HA, Correa AM, Wu TT, Bruzzi JF, Marom EM, Sabloff BS, Ajani JA, Komaki R, Liao Z, Lee JH, Fukami N, Bresalier R, Swisher SG. Preoperative chemo-radiation-induced ulceration in patients with esophageal cancer: a confounding factor in tumor response assessment in integrated computed tomographic-positron emission tomographic imaging. J Thorac Oncol 1(5):478-86, 2006. PMID: 17409902.
98. Santiago JF, Gonen M, Yeung H, Macapinlac HA, Larson S. A retrospective analysis of the impact of 18F-FDG PET scans on clinical management of 133 breast cancer patients. Q J Nucl Med Mol Imaging 50(1):61-7, 2006. PMID: 16557205.
99. Bruzzi JF, Macapinlac HA, Tsimberidou AM, Truong MT, Keating MJ, Marom EM, Munden RF. Detection of Richter's transformation of chronic lymphocytic leukemia by PET/CT. J Nucl Med 47(8):1267-73, 2006. PMID: 16883004.
100. Macapinlac HA. Positron emission tomography of the brain. Neuroimaging Clin N Am 16(4):591-603, 2006. PMID: 17148021.
101. Mawlawi O, Erasmus JJ, Munden RF, Pan T, Knight AE, Macapinlac HA, Podoloff DA, Chasen M. Quantifying the effect of IV contrast media on integrated PET/CT: clinical evaluation. AJR Am J Roentgenol 186(2):308-19, 2006. PMID: 16423932.
102. Mawlawi O, Erasmus JJ, Pan T, Cody DD, Campbell R, Lonn AH, Kohlmyer S, Macapinlac HA, Podoloff DA. Truncation artifact on PET/CT: impact on measurements of activity concentration and assessment of a correction algorithm. AJR Am J Roentgenol 186:1458-67, 2006. PMID: 16632745.
103. Mawlawi O, Pan T, Macapinlac HA. PET/CT imaging techniques, considerations, and artifacts. J Thorac Imaging 21(2):99-110, 2006. PMID: 16770227.
104. Munden RF, Macapinlac HA, Erasmus JJ. Esophageal cancer: the role of integrated CT-PET in initial staging and response assessment after preoperative therapy. J Thorac Imaging 21(2):137-45, 2006. PMID: 16770230.
105. Pan T, Mawlawi O, Luo D, Liu HH, Chi PC, Mar MV, Gladish G, Truong M, Erasmus J, Jr, Liao Z, Macapinlac HA. Attenuation correction of PET cardiac data with low-dose average CT in PET/CT. Med Phys 33(10):3931-8, 2006. PMID: 17089855.
106. Pawlik TM, Erasmus JJ, Truong MT, Macapinlac HA, Ross MI, Gershenwald JE. Acne vulgaris: false-positive finding on integrated 18F-FDG PET/CT in a patient with melanoma. Am J Roentgenol 187(1):W117-9, 2006. PMID: 16794124.
107. Trent JC, Ramdas L, Dupart J, Hunt K, Macapinlac HA, Taylor E, Hu L, Salvado A, Abbruzzese JL, Pollock R, Benjamin RS, Zhang W. Early effects of imatinib mesylate on the expression of insulin-like growth factor binding protein-3 and positron emission tomography in patients with gastrointestinal stromal tumor. Cancer 107(8):1898-908, 2006. PMID: 16986125.
108. Sasaki R, Komaki R, Macapinlac HA, Erasmus J, Allen P, Forster K, Putnam JB, Herbst RS, Moran CA, Podoloff DA, Roth JA, Cox JD. [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol 23(6):1136-43, 2005. PMID: 15718309.
109. Pan T, Mawlawi O, Nehmeh SA, Erdi YE, Luo D, Liu HH, Castillo R, Mohan R, Liao Z, Macapinlac HA. Attenuation correction of PET images with respiration-averaged CT images in PET/CT. J Nucl Med 46(9):1481-7, 2005. PMID: 16157531.
110. Martinez-Roman S, Ramirez PT, Oh J, Viciedo MG, Macapinlac HA. Combined positron emission tomography and computed tomography for the detection of recurrent ovarian mucinous adenocarcinoma. Gynecol Oncol 96(3):888-91, 2005. PMID: 15721446.
111. Kazama T, Swanston N, Podoloff DA, Macapinlac HA. Effect of colony-stimulating factor and conventional- or high-dose chemotherapy on FDG uptake in bone marrow. Eur J Nucl Med Mol Imaging 32(12):1406-11, 2005. PMID: 16133379.
112. Kazama T, Faria SC, Varavithya V, Phongkitkarun S, Ito H, Macapinlac HA. FDG PET in the evaluation of treatment for lymphoma: clinical usefulness and pitfalls. Radiographics 25(1):191-207, 2005. PMID: 15653595.
113. Macapinlac HA. FDG-PET in head and neck, and thyroid cancer. Chang Gung Med J 28(5):284-95, 2005. PMID: 16086543.
114. Macapinlac HA. FDG-PET in the evaluation of cervical cancer. Gynecol Oncol 99(3 Suppl 1):S171-2, 2005. PMID: 16419203.
115. Yi JG, Marom EM, Munden RF, Truong MT, Macapinlac HA, Gladish GW, Sabloff BS, Podoloff DA. Focal uptake of fluorodeoxyglucose by the thyroid in patients undergoing initial disease staging with combined PET/CT for non-small cell lung cancer. Radiology 236(1):271-5, 2005. PMID: 15987980.
116. Chen LL, Sabripour M, Andtbacka RH, Patel SR, Feig BW, Macapinlac HA, Choi H, Wu EF, Frazier ML, Benjamin RS. Imatinib resistance in gastrointestinal stromal tumors. Curr Oncol Rep 7(4):293-9, 2005. PMID: 15946589.
117. Erasmus JJ, Truong MT, Smythe WR, Munden RF, Marom EM, Rice DC, Vaporciyan AA, Walsh GL, Sabloff BS, Broemeling LD, Stevens CW, Pisters KM, Podoloff DA, Macapinlac HA. Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: Staging implications. J Thorac Cardiovasc Surg 129(6):1364-70, 2005. PMID: 15942579.
118. Truong MT, Erasmus JJ, Macapinlac HA, Marom EM, Mawlawi O, Gladish GW, Sabloff BS, Bruzzi JF, Munden RF. Integrated positron emission tomography/computed tomography in patients with non-small cell lung cancer: normal variants and pitfalls. J Comput Assist Tomogr 29(2):205-209, 2005. PMID: 15772538.
119. Phongkitkarun S, Varavithya V, Kazama T, Faria SC, Mar MV, Podoloff DA, Macapinlac HA. Lymphomatous involvement of gastrointestinal tract: evaluation by positron emission tomography with (18)F-fluorodeoxyglucose. World J Gastroenterol 11(46):7284-9, 2005. PMID: 16437629.
120. Frank SJ, Chao KS, Schwartz DL, Weber RS, Apisarnthanarax S, Macapinlac HA. Technology insight: PET and PET/CT in head and neck tumor staging and radiation therapy planning. Nat Clin Pract Oncol 2(10):526-33, 2005. PMID: 16205772.
121. Macapinlac HA. FDG PET and PET/CT imaging in lymphoma and melanoma. Cancer J 10:262-70, 2004. PMID: 15383207.
122. Swisher SG, Erasmus J, Maish M, Correa AM, Macapinlac HA, Ajani JA, Cox JD, Komaki RR, Hong D, Lee HK, Putnam JB, Jr, Rice DC, Smythe WR, Thai L, Vaporciyan AA, Walsh GL, Wu TT, Roth JA. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer 101(18):1776-85, 2004. PMID: 15386332.
123. Choi H, Charnsangavej C, de Castro Faria S, Tamm EP, Benjamin RS, Johnson MM, Macapinlac HA, Podoloff DA. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. AJR Am J Roentgenol 183(6):1619-28, 2004. PMID: 15547201.
124. Truong MT, Erasmus JJ, Munden RF, Marom EM, Sabloff BS, Gladish GW, Podoloff DA, Macapinlac HA. Focal FDG uptake in mediastinal brown fat mimicking malignancy: a potential pitfall resolved on PET/CT. AJR Am J Roentgenol 183(4):1127-32, 2004. PMID: 15385319.
125. Chen LL, Trent JC, Wu EF, Fuller GN, Ramdas L, Zhang W, Raymond AK, Prieto VG, Oyedeji CO, Hunt KK, Pollock RE, Feig BW, Hayes KJ, Choi H, Macapinlac HA, Hittelman W, Velasco MA, Patel S, Burgess MA, Benjamin RS, Frazier ML. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res 64(17):5913-9, 2004. PMID: 15342366.
126. Mawlawi O, Podoloff DA, Kohlmyer S, Williams JJ, Stearns CW, Culp RF, Macapinlac HA. Performance characteristics of a newly developed PET/CT scanner using NEMA standards in 2D and 3D modes. J Nucl Med 45(10):1734-42, 2004. PMID: 15471842.
127. Gayed I, Vu T, Iyer R, Johnson M, Macapinlac HA, Swanston N, Podoloff D. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J Nucl Med 45(1):17-21, 2004. PMID: 14734662.
128. Truong MT, Erasmus JJ, Macapinlac HA, Podoloff DA. Teflon injection for vocal cord paralysis: false-positive finding on FDG PET-CT in a patient with non-small cell lung cancer. AJR Am J Roentgenol 182(6):1587-9, 2004. PMID: 15150014.
129. Macapinlac HA. The utility of 2-deoxy-2-[18F]fluoro-D-glucose-positron emission tomography and combined positron emission tomography and computed tomography in lymphoma and melanoma. Mol Imaging Biol 6(4):200-7, 2004. PMID: 15262235.
130. Swisher SG, Maish M, Erasmus JJ, Correa AM, Ajani JA, Bresalier R, Komaki R, Macapinlac HA, Munden RF, Putnam JB, Rice D, Smythe WR, Vaporciyan AA, Walsh GL, Wu TT, Roth JA. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg 78(4):1152-60; discussion 1152-60, 2004. PMID: 15464463.
131. Gayed I, Vu T, Johnson M, Macapinlac HA, Podoloff D. Comparison of bone and 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in the evaluation of bony metastases in lung cancer. Mol Imaging Biol 5(1):26-31, 2003. PMID: 14499159.
132. Turlakow A, Yeung HW, Salmon AS, Macapinlac HA, Larson SM. Peritoneal carcinomatosis: role of (18)F-FDG PET. J Nucl Med 44(9):1407-1412, 2003. PMID: 12960184.
133. Reed CE, Harpole DH, Posther KE, Woolson SL, Downey RJ, Meyers BF, Heelan RT, Macapinlac HA, Jung SH, Silvestri GA, Siegel BA, Rusch VW. Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer. J Thorac Cardiovasc Surg 126(6):1943-1951, 2003. PMID: 14688710.
134. Nunez R, Macapinlac HA, Yeung HW, Akhurst T, Cai S, Osman I, Gonen M, Riedel E, Scher HI, Larson SM. Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer. J Nucl Med 43(1):46-55, 2002. PMID: 11801702.
135. Nehmeh SA, Erdi YE, Ling CC, Rosenzweig KE, Schoder H, Larson SM, Macapinlac HA, Squire OD, Humm JL. Effect of respiratory gating on quantifying PET images of lung cancer. J Nucl Med 43(7):876-881, 2002. PMID: 12097456.
136. Sanchez Salmon A, Nunez R, Yeung H, Healey J, Macapinlac HA. FGD PET in a patient with pseudofractures from osteomalacia. Rev Esp Med Nucl 21(1):34-35, 2002. PMID: 11821000.
137. Morris MJ, Akhurst T, Osman I, Nunez R, Macapinlac HA, Siedlecki K, Verbel D, Schwartz L, Larson SM, Scher HI. Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology 59(6):913-918, 2002. PMID: 12031380.
138. Etchebehere EC, Macapinlac HA, Gonen M, Humm K, Yeung HW, Akhurst T, Scher HI, Larson SM. Qualitative and quantitative comparison between images obtained with filtered back projection and iterative reconstruction in prostate cancer lesions of (18)F-FDG PET. Q J Nucl Med 46(2):122-130, 2002. PMID: 12114875.
139. Erdi YE, Rosenzweig K, Erdi AK, Macapinlac HA, Hu YC, Braban LE, Humm JL, Squire OD, Chui CS, Larson SM, Yorke ED. Radiotherapy treatment planning for patients with non-small cell lung cancer using positron emission tomography (PET). Radiother Oncol 62:51-60, 2002. PMID: 11830312.
140. Yeung HW, Sanches A, Squire OD, Macapinlac HA, Larson SM, Erdi YE. Standardized uptake value in pediatric patients: an investigation to determine the optimum measurement parameter. Eur J Nucl Med Mol Imaging 29:61-66, 2002. PMID: 11807608.
141. Turlakow A, Yeung HW, Pui J, Macapinlac HA, Liebovitz E, Rusch V, Goy A, Larson SM. Fludeoxyglucose positron emission tomography in the diagnosis of giant cell arteritis. Arch Intern Med 161(7):1003-7, 2001. PMID: 11295964.
142. Ramos CD, Chisin R, Yeung HW, Larson SM, Macapinlac HA. Incidental focal thyroid uptake on FDG positron emission tomographic scans may represent a second primary tumor. Clin Nucl Med 26(3):193-197, 2001. PMID: 11245108.
143. Macapinlac HA. Clinical usefulness of FDG PET in differentiated thyroid cancer. J Nucl Med 42(1):77-8, 2001. PMID: 11197984.
144. Ramos CD, Erdi YE, Gonen M, Riedel E, Yeung HW, Macapinlac HA, Chisin R, Larson SM. FDG-PET standardized uptake values in normal anatomical structures using iterative reconstruction segmented attenuation correction and filtered back-projection. Eur J Nucl Med 28:155-164, 2001. PMID: 11303885.
145. Turlakow A, Larson SM, Coakley F, Akhurst T, Gonen M, Macapinlac HA, Kelly W, Leibel S, Humm J, Scardino P, Scher H, Hricak H. Local detection of prostate cancer by positron emission tomography with 2-fluorodeoxyglucose: comparison of filtered back projection and iterative reconstruction with segmented attenuation correction. Q J Nucl Med 45(3):235-424, 2001. PMID: 11788816.
146. Chisin R, Macapinlac HA. The indications of FDG-PET in neck oncology. Radiol Clin North Am 38(5):999-1012, 2000. PMID: 11054965.
147. Imbriaco M, Akhurst T, Hilton S, Yeung HW, Macapinlac HA, Mazumdar M, Pace L, Kemeny N, Erdi Y, Cohen A, Fong Y, Guillem J, Larson SM. Whole-Body FDG-PET in Patients with Recurrent Colorectal Carcinoma. A Comparative Study with CT. Clin Positron Imaging 3(3):107-114, 2000. PMID: 11008100.
148. McCaffrey JA, Reuter VV, Herr HW, Macapinlac HA, Russo P, Motzer RJ. Carcinoid tumor of the kidney. The use of somatostatin receptor scintigraphy in diagnosis and management. Urol Oncol 5(3):108-111, 2000. PMID: 10765017.
149. Wang W, Larson SM, Fazzari M, Tickoo SK, Kolbert K, Sgouros G, Yeung H, Macapinlac HA, Rosai J, Robbins RJ. Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab 85(3):1107-13, 2000. PMID: 10720047.
150. Robbins RJ, Voelker E, Wang W, Macapinlac HA, Larson SM. Compassionate use of recombinant human thyrotropin to facilitate radioiodine therapy: case report and review of literature. Endocr Pract 6(6):460-464, 2000. PMID: 11155220.
151. Nunez RF, Yeung HW, Macapinlac HA, Castro-Malaspina H, Larson SM. Ga-67 uptake in cutaneous lesions of graft-versus-host disease. Clin Nucl Med 25(9):676-678, 2000. PMID: 10983752.
152. Robbins RJ, Hill RH, Wang W, Macapinlac HA, Larson SM. Inhibition of metabolic activity in papillary thyroid carcinoma by a somatostatin analogue. Thyroid 10(2):177-183, 2000. PMID: 10718556.
153. Guillem JG, Puig-La Calle J, Jr, Akhurst T, Tickoo S, Ruo L, Minsky BD, Gollub MJ, Klimstra DS, Mazumdar M, Paty PB, Macapinlac HA, Yeung H, Saltz L, Finn RD, Erdi Y, Humm J, Cohen AM, Larson S. Prospective assessment of primary rectal cancer response to preoperative radiation and chemotherapy using 18-fluorodeoxyglucose positron emission tomography. Dis Colon Rectum 43(1):18-24, 2000. PMID: 10813118.
154. Motzer RJ, Mazumdar M, Sheinfeld J, Bajorin DF, Macapinlac HA, Bains M, Reich L, Flombaum C, Mariani T, Tong WP, Bosl GJ. Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients. J Clin Oncol 18(6):1173-1180, 2000. PMID: 10715285.
155. Erdi YE, Macapinlac HA, Rosenzweig KE, Humm JL, Larson SM, Erdi AK, Yorke ED. Use of PET to monitor the response of lung cancer to radiation treatment. Eur J Nucl Med 27(7):861-866, 2000. PMID: 10952499.
156. Macapinlac HA, Yeung HW, Larson SM. Defining the Role of FDG PET in Head and Neck Cancer. Clin Positron Imaging 2(6):311-316, 1999. PMID: 14516613.
157. Rini JN, Yeung HW, Nunez RF, la Calle JP, Larson S, Macapinlac HA. FDG-PET Patterns of Abdominal Carcinomatosis. Clin Positron Imaging 2(6):333, 1999. PMID: 14516630.
158. Wang W, Macapinlac HA, Larson SM, Yeh SD, Akhurst T, Finn RD, Rosai J, Robbins RJ. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab 84:2291-302, 1999. PMID: 10404792.
159. Macapinlac HA, Humm JL, Akhurst T, Osman I, Pentlow K, Shangde C, Yeung HW, Squire O, Finn RD, Scher HI, Larson SM. Differential Metabolism and Pharmacokinetics of L-[1-(11)C]-Methionine and 2-[(18)F] Fluoro-2-deoxy-D-glucose (FDG) in Androgen Independent Prostate Cancer. Clin Positron Imaging 2(3):173-181, 1999. PMID: 14516541.
160. Yeung HW, Macapinlac HA, Mazumdar M, Bains M, Finn RD, Larson SM. FDG-PET in Esophageal Cancer. Incremental Value over Computed Tomography. Clin Positron Imaging 2:255-260, 1999. PMID: 14516649.
161. Nunez RF, Yeung HW, Macapinlac HA. Increased F-18 FDG uptake in the stomach. Clin Nucl Med 24:281-282, 1999. PMID: 10466532.
162. Erdi YE, Macapinlac HA, Larson SM, Erdi AK, Yeung H, Furhang EE, Humm JL. Radiation Dose Assessment for I-131 Therapy of Thyroid Cancer Using I-124 PET Imaging. Clin Positron Imaging 2(1):41-46, 1999. PMID: 14516552.
163. Larson SM, Erdi Y, Akhurst T, Mazumdar M, Macapinlac HA, Finn RD, Casilla C, Fazzari M, Srivastava N, Yeung HW, Humm JL, Guillem J, Downey R, Karpeh M, Cohen AE, Ginsberg R. Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging. The Visual Response Score and the Change in Total Lesion Glycolysis. Clin Positron Imaging 2(3):159-171, 1999. PMID: 14516540.
164. Fong Y, Saldinger PF, Akhurst T, Macapinlac HA, Yeung H, Finn RD, Cohen A, Kemeny N, Blumgart LH, Larson SM. Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases. Am J Surg 178(4):282-287, 1999. PMID: 10587184.
165. Adler ML, Macapinlac HA, Robbins RJ. Radioiodine treatment of thyroid cancer with the aid of recombinant human thyrotropin. Endocr Pract 4(5):282-286, 1998. PMID: 15251726.
166. Yeung HW, Macapinlac HA, Karpeh M, Finn RD, Larson SM. Accuracy of FDG-PET in Gastric Cancer. Preliminary Experience. Clin Positron Imaging 1(4):213-221, 1998. PMID: 14516555.
167. Akhurst T, Boland P, Macapinlac HA, Finn R, Yeung HW, Squire O, Larson SM. Excess Muscle FDG Uptake in an Euglycaemic Patient That Is Corrected by Fasting. Clin Positron Imaging 1(2):131-133, 1998. PMID: 14516602.
168. Macapinlac HA, Larson SM. Positron emission tomography (PET)--measured biochemical response to radiotherapy of laryngeal tumors. Cancer J Sci Am 3(6):333-335, 1997. PMID: 9403044.
169. El-Shirbiny AM, Yeung H, Imbriaco M, Michaeli J, Macapinlac HA, Larson SM. Technetium-99m-MIBI versus fluorine-18-FDG in diffuse multiple myeloma. J Nucl Med 38(8):1208-1210, 1997. PMID: 9255151.
170. Yeung H, Macapinlac HA. First impressions. A 21-yr-old woman with adenocarcinoma of the pelvis. What is the radiopharmaceutical? What are the findings?. J Nucl Med 37(12):7A, 1994, 1996. PMID: 8999117.
171. Yeung HW, Imbriaco M, Zhang JJ, Macapinlac HA, Goldsmith SJ, Larson SM. Visualization of myocardial metastasis of carcinoid tumor by indium-111-pentetreotide. J Nucl Med 37(9):1528-30, 1996. PMID: 8790210.
172. Macapinlac HA, Kemeny N, Daghighian F, Finn R, Zhang J, Humm J, Squire O, Larson SM. Pilot clinical trial of 5-[125I]iodo-2'-deoxyuridine in the treatment of colorectal cancer metastatic to the liver. J Nucl Med 37(4 Suppl):25S-29S, 1996. PMID: 8676200.
173. Daghighian F, Humm JL, Macapinlac HA, Zhang J, Izzo J, Finn R, Kemeny N, Larson SM. Pharmacokinetics and dosimetry of iodine-125-IUdR in the treatment of colorectal cancer metastatic to liver. J Nucl Med 37(4 Suppl):29S-32S, 1996. PMID: 8676201.
174. Abdel-Dayem H, Bag R, Macapinlac HA, Elgazzar AH, Habbab N, Pescatore F, Kempf J. Diffuse Tl-201 uptake in the lungs. Etiologic classification and pattern recognition. Clin Nucl Med 20(2):164-72, 1995. PMID: 7720309.
175. Caluser C, Scott A, Macapinlac HA, Yeh S, Rosenfelt N, Farid B, Abdel-Dayem HM, Larson SM, Kalaigian H. Extramedullary hematopoiesis assessment in a patient with osteopetrosis. Clin Nucl Med 20(1):75, 1995. PMID: 7895447.
176. Scott AM, Macapinlac HA, Zhang J, Daghighian F, Montemayor N, Kalaigian H, Sgouros G, Graham MC, Kolbert K, Yeh SD. Image registration of SPECT and CT images using an external fiduciary band and three-dimensional surface fitting in metastatic thyroid cancer. J Nucl Med 36:100-103, 1995. PMID: 7799059.
177. Goldsmith SJ, Macapinlac HA, O'Brien JP. Somatostatin receptor imaging in lymphoma. Semin Nucl Med 25(3):262-271, 1995. PMID: 7570045.
178. Reinsel RA, Veselis RA, Feshchenko VA, Di Resta GR, Mawlawi O, Beattie B, Silbersweig D, Stern E, Blasberg R, Macapinlac HA. Target detection and the prefrontal cortex. A PET scan study of the P300 event-related potential. Ann N Y Acad Sci 769:393-397, 1995. PMID: 8595041.
179. Larson, SM, Divgi, CR, Scott, AM, Daghighian, F, Macapinlac, HA, Welt, S. Current status of radioimmunodetection. Nucl Med Biol 215(5):721-729, 1994. PMID: 9241648.
180. Scott AM, Macapinlac HA, Zhang JJ, Kalaigian H, Graham MC, Divgi CR, Sgouros G, Goldsmith SJ, Larson SM. Applications of fusion imaging in oncology. Nucl Med Biol 21(5):775-784, 1994. PMID: 9241654.
181. Scott AM, Macapinlac HA, Divgi CR, Zhang JJ, Kalaigian H, Pentlow K, Hilton S, Graham MC, Sgouros G, Pelizzari C, et al. Clinical validation of SPECT and CT/MRI image registration in radiolabeled monoclonal antibody studies of colorectal carcinoma. J Nucl Med 35(12):1976-84, 1994. PMID: 7989980.
182. Schneider JA, Divgi CR, Scott AM, Macapinlac HA, Seidman AD, Goldsmith SJ, Larson SM. Flare on bone scintigraphy following Taxol chemotherapy for metastatic breast cancer. J Nucl Med 35(11):1748-1752, 1994. PMID: 7525900.
183. Macapinlac HA, Scott AM, Larson SM, Divgi CR, Yeh SD, Goldsmith SJ. Gallium-67-citrate imaging in nuclear oncology. Nucl Med Biol 21(5):731-738, 1994. PMID: 9241649.
184. Tjuvajev JG, Macapinlac HA, Daghighian F, Scott AM, Ginos JZ, Finn RD, Kothari P, Desai R, Zhang J, Beattie B, et al. Imaging of brain tumor proliferative activity with iodine-131-iododeoxyuridine. J Nucl Med 35(14):1407-1418, 1994. PMID: 8071684.
185. Abdel-Dayem HM, Scott A, Macapinlac HA, Larson S. Tracer imaging in lung cancer. Eur J Nucl Med 21(1):57-81, 1994. PMID: 8088287.
186. Caluser CI, Abdel-Dayem HM, Macapinlac HA, Scott A, Healey JH, Huvos A, Kalaigian H, Yeh SD, Larson SM. The value of thallium and three-phase bone scans in the evaluation of bone and soft tissue sarcomas. Eur J Nucl Med 21:1198-1205, 1994. PMID: 7859771.
187. Rusch V, Macapinlac HA, Heelan R, Kramer E, Larson S, McCormack P, Burt M, Martini N, Ginsberg R. NR-LU-10 monoclonal antibody scanning. A helpful new adjunct to computed tomography in evaluating non-small-cell lung cancer. J Thorac Cardiovasc Surg 106(2):200-4, 1993. PMID: 8393504.
188. Daghighian F, Pentlow KS, Larson SM, Graham MC, DiResta GR, Yeh SD, Macapinlac HA, Finn RD, Arbit E, Cheung NK. Development of a method to measure kinetics of radiolabelled monoclonal antibody in human tumour with applications to microdosimetry: positron emission tomography studies of iodine-124 labelled 3F8 monoclonal antibody in glioma. Eur J Nucl Med 20(5):402-9, 1993. PMID: 8519259.
189. Schneider JA, Divgi CR, Scott AM, Macapinlac HA, Sonenberg M, Goldsmith SJ, Larson SM. Hiatal hernia on whole-body radioiodine survey mimicking metastatic thyroid cancer. Clin Nucl Med 18(9):751-753, 1993. PMID: 8403716.
190. Larson SM, Macapinlac HA, Scott AM, Divgi CR. Recent achievements in the development of radiolabeled monoclonal antibodies for diagnosis, therapy and biologic characterization of human tumors. Acta Oncol 32(7/8):709-715, 1993. PMID: 8305216.
191. Roistacher N, Preminger M, Macapinlac HA, Pierri MK. Myocardial entrapment by lymphoma: a cause of reversible segmental left ventricular dysfunction. Am Heart J 124(2):516-521, 1992. PMID: 1636600.
192. Caluser C, Macapinlac HA, Healey J, Ghavimi F, Meyers P, Wollner N, Kalaigian J, Kostakoglu L, Abdel-Dayem HM, Yeh SD, et al. The relationship between thallium uptake, blood flow, and blood pool activity in bone and soft tissue tumors. Clin Nucl Med 17(7):565-72, 1992. PMID: 1638838.
193. Caluser C, Healey J, Macapinlac HA, Kostakoglu L, Abdel-Dayem HM, Larson SM, Yeh SD. Thallium uptake in recurrent pigmented villonodular synovitis. Correlation with three-phase bone scanning. Clin Nucl Med 17(9):751-3, 1992. PMID: 1395357.
194. Hoener B, Engelstad BL, Ramos EC, Macapinlac HA, Price DC, Johnson TR, White DL. Comparison of Fe-HBED and Fe-EHPG as hepatobiliary MR contrast agents. J Magn Reson Imaging 1:357-62, 1991. PMID: 1802149.

Invited Articles

1. Macapinlac HA, Larson SM. Positron Emission Tomography (PET)-measured biochemical response to radiotherapy of laryngeal tumors. Cancer J Sci Am 3(6):333-5, 1997.
2. Abdel-Dayem HM, Scott A, Macapinlac HA, Larson S. Tracer imaging in lung cancer. Eur J Nucl Med (1):57-81, 1994.
3. Macapinlac HA, Larson SM. Whole body PET in oncology. Oncology 7(7):52-55, 1993.

Manuals, Teaching Aids, Other Teaching Publications

1. Larson SM, Macapinlac HA, Shankar LK. RSP2907RC - Molecular Imaging in Oncology (2008). RSNA: Chicago, 2008.
2. Macapinlac HA. Cardinal Health: PET Champions Series Home Study CD: PET in Radiation Planning, PET in Head/Neck Cancer, PET in Lung Cancer, 2007.
3. Macapinlac HA. Educational Symposia DVD: 2005 PET-CT Imaging in Clinical Practice & PET-CT for Radiation Therapy, 2005.
4. Macapinlac HA. GE Healthcare Videotape/CD: PET Oncology Fundamentals for Reading & Referring Physicians, 2001.
5. Larson SM, Macapinlac HA, Yeung HWD, Rigo P. Clinical PET in Oncology. Williams & Wilkins, 1996.

Other Articles

1. Nunez R, Yeung HW, Swanston NM, Macapinlac HA FDG uptake in gall bladder in the PET and PET/CT scan of three oncology patients. Rev Esp Med Nucl 26(4):234-6, 2007.

Editorials

1. Lu Y, Sweiss NJ, Macapinlac HA. What Is the Optimal Method on Myocardial Suppression in FDG PET/CT Evaluation of Cardiac Sarcoidosis?. Clin Nucl Med 46(11):904-905, 2021. PMID: 34132675.

Abstracts

1. Kairemo KJ, Jessop A, Kappadath SC, Macapinlac HA. A prospective comparative study of using ultrasonography (US), 4D-CT and parathyroid dual-phase scintigraphy with SPECT in patients with primary hyperparathyreoidism. SNMMI Annual Meeting 2016, 2016.
2. Kim MP, Correa AM, Lee J, Rice DC, Roth JA, Mehran RJ, Walsh GL, Ajani JA, Maru DM, Chang JY, Marom EM, Macapinlac HA, Lee JH, Vaporciyan AA, Rice T, Swisher SG, Hofstetter WL. Pathologic T0N1 after neoadjuvant therapy and surgery for esophageal cancer: an orphan status. 46th Annual Meeting Program, The Society of Thoracic Surgeons(44):174-175, 2010.
3. Yoo DC, Hillman S, Macapinlac HA, Fernando H, Rilling WS, Shepard JO, et al.. F-18 FDC PET/CT in Stage 1A NSCLC after RFA: Initial Report from a Cooperative Group Trial - American College of Surgeons Oncology Group Z4033. RSNA 2009 Scientific Assembly and Annual Meeting Program:688, 2009.
4. Chang T, Pan T, Riegel A, Chang G, Rohren E, Macapinlac H, Mawlawi O. Comparison of internal target volumes for treatment planning using CT and PET. J Nucl Med 49:325P, 2008.
5. Riegel A, Mawlawi O, Rohren E, Macapinlac H, Pan T. Determination of PET thresholds for solitary pulmonary tumors in radiation treatment planning. J Nucl Med 49:382P, 2008.
6. Pan T, Gould L, Mawlawi O, Gladish, Rohren E, Macapinlac H. Assessment of heart motion during respiration with cine CT without gating in cardiac PET. J Nucl Med 49:384P, 2008.
7. Pan T, Gould L, Mawlawi O, Mar M, Rohren E, Macapinlac H. Investigation of helical CT with rigid body translation for attenuation correction of cardiac PET data. J Nucl Med 49:390P, 2008.
8. Chang T, Pan T, Chang G, Rohren E, Macapinlac H, Mawlawi O. Effects of scan duration and count density on the quantitative accuracy of PET images. J Nucl Med 49:395P, 2008.
9. Jackson J, Smith A, Swanston N, Chasen B, Fitzgerald N, Rohren E, Macapinlac H. Bismuth shielding: A tool to reduce CT dose to female pediatric breast tissue during PET/CT acquisition, while not compromising image data. J Nucl Med 59:416P, 2008.
10. Jackson J, Smith A, Pan T, Swanston N, Rohren E, Macapinlac H. Bismuth shielding: Evaluation of benefits and effects on PET/CT acquisition. J Nucl Med 49:422P, 2008.
11. Mar MV, Miller SA, Kim, EE, Macapinlac HA. Evaluation and localization of lymphatic drainage and sentinel lymph nodes in patients with head and neck melanomas by hybrid SPECT/CT. J Nucl Med 35(1):10-16, 2007.
12. Nunez R, Namwongprom S, Stachowiak A, Mar M, Yeung H, Macapinlac H. Added value of SPECT/Multislice CT over diagnostic whole body planar imaging in patients with thyroid carcinoma. J Nucl Med 48:266P-a, 2007.
13. Mawlawi O, Erwin W, Pan T, Wendt III R, Chasen B, Nunez R, Yeung H, Macapinlac H. What is the optimal minimum whole body bone SPECT scan duration that can replace planar bone scintigraphy?. J Nucl Med 48:120P-c, 2007.
14. Chi PC, Mawlawi O, Yeung H, Macapinlac H, Pan T. Effect of average CT on quantifying PET images of lung cancer. J Nucl Med 48:96P, 2007.
15. Jackson J, Pan T, Swanston N, Macapinlac H, Podoloff D, Mawlawi O. Effects of detector malfunction on PET quantification accuracy. J Nucl Med 48:462P, 2007.
16. Mawlawi O, Yahil A, Vija H, Erwin W, Macapinlac H. Reduction in scan duration or injected dose in planar bone scintigraphy enabled by Pixon® post-processing. J Nucl Med 48:13P-b, 2007.
17. Jackson J, Pan T, Swanston N, Macapinlac H, Podoloff D. Strategy to reduce CT dose and maintain image quality for small body habitus patients in PET/CT. J Nucl Med 48:450P-b, 2007.
18. Mawlawi O, Truong M, Marom E, Pan T, Sabloff B, Bruzzi J, Erasmus J, Yeung H, Macapinlac H. Clinical evaluation of 2D versus 3D whole body FDG imaging performed on two PET scanners with different detectors. J Nucl Med 48:442P-a, 2007.
19. Dickinson R, Mar M, Erwin W, Bidaut L, Mawlawi O, Macapinlac H, Wendt R. Investigation of a novel approach to localizing the sentinel node in breast lymphoscintigraphy: Fusion of planar scintigrams and CT topograms. J Nucl Med 48:425P-a, 2007.
20. Tonkopi E, Mawlawi O, Chi PC, Yeung H, Macapinlac H, Pan T. Effect of Average CT on quantifying PET images of colorectal cancer metastasis in the liver. J Nucl Med 48:411P-a, 2007.
21. Pan T, Mawlawi O, Nehmeh S, Erdi Y, Chi P, Luo D, Truong M, Erasmus J, Macapinlac H. New low dose cine CT for quantitation of the PET data in the thorax on PET/CT. J Nucl Med 47:395P, 2006.
22. Mawlawi O, Pan T, Qiao F, Devaraju V, Lofton B, Truong M, Macapinlac H. How long should gated PET/CT scans be in order to generate individual images with good quality??. J Nucl Med 47:388P-b, 2006.
23. Pan T, Mawlawi O, Nehmeh S, Erdi Y, Chi PC, Luo D, Truong M, Erasmus J, Macapinlac H. Attenuation correction of cardiac PET data with respiration-averaged CT on PET/CT data with respiration-averaged CT on PET/CT. J Nucl Med 47(385P-a), 2006.
24. Mawlawi O, Pan T, Baghaei H, Swanston N, Darensborg B, Erasmus J, Macapinlac H. A comparison of lesion detectability among four different PET scanners. J Nucl Med 47(366P-a), 2006.
25. Pan T, Hamill J, Luo D, Mawlawi O, Macapinlac H. PET imaging of the thorax with attenuation correction by time-averaging and attenuation-averaging of CT data from 4DCT. J Nucl Med 47:192P-b, 2006.
26. Mawlawi O, Erwin W, Pan T, Bartosh J, Kim E, Macapinlac H. Can whole body bone SPECT replace planar imaging when acquired over a similar duration?. J Nucl Med 47:62P-a, 2006.
27. Pan T, Mawlawi O, Nehmeh SA, Erdi YE, Luo D, Liu HH, Castillo R, Mohan R, Liao Z, Macapinlac HA. Attenuation correction of PET images with respiration-averaged CT images in PET/CT. J Nucl Med 46(9):1481-1487, 2005.
28. Gayed I, Vu T, Iyer R, Johnson M, Macapinlac H, Swanston N, Podoloff D. The role of F18-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J Nucl Med 45(1):17-21, 2004.
29. Mawlawi O, Podoloff DA, Kohlmyer S, Williams JJ, Stearns CW, Culp RF, Macapinlac HA. Performance characteristics of a newly developed PET/CT scanner using NEMA standards in 2D and 3D modes. J Nucl Med 45(10):1734-1742, 2004.
30. Gayed I, Vu T, Johnson M, Macapinlac HA, Podoloff DA. Comparison of bone and 2-deoxy-2-(18F) fluoroglucose positron emission tomography in the evaluation of bony metastases in lung cancer. Mol Imaging Biol 5(1):26-31P, 2003.
31. Mawlawi O, Kohlmyer S, Podoloff DA, Macapinlac H. Evaluation of clinical image quality and lesion detectability of the discovery ST (DST) PET/CT scanner. J Nucl Med 44 (Suppl)(5):282p, 2003.
32. Varavithya V, Phongkitkarun S, Kazama T, Faria SC, Mar M, Podoloff DA, Macapinlac HA. FDG-PET in Lymphoma of the liver: Lesion detection by FDG-PET vs. CT. J Nucl Med 44(5):83P, 2003.
33. Kazama T, Swanston N, Podoloff DA, Macapinlac HA. Granulocyte colony stimulating factor: an investigation on increased uptake and optimal length of time for diagnosis when used with F-18 FDG PET. J Nucl Med 44(5):187p, 2003.
34. Forster KM, Mawlawi O, Cody D, Steadham RE, Chao C, Guerrero R, Komaki R, Kohlmyer S, Macapinlac H. Identification of acceptance criteria and testing of a PET/CT scanner for radiotherapy treatment planning. J Nucl Med 44 (Suppl)(5):291p, 2003.
35. Phongkitkarun S, Varavithya V, Kazama T, Faria SC, Mar M, Podoloff DA, Macapinlac HA. Lymphomatous involvement of the gastrointestinal tract: evaluation by positron emission tomography (PET) with 18F-Fluorodeoxyglucose (18F-FDG). J Nucl Med 44(5):83p, 2003.
36. Mawlawi O, Kohlmyer S, Williams JJ, Stearns CW, Culp RF, Podoloff DA, Macapinlac HA. Performance characteristics of the GE discovery ST PET/CT scanner using the nema standard. J Nucl Med 44(5):111p, 2003.
37. Turkakow A, Yeung HW, Salmon AS, Macapinlac HA, Larson SM. Peritoneal Carcinomatosis: Role of (18)F-FDG PET. J Nucl Med 44(9):1407-9, 2003.
38. Sasaki R, Komaki R, Macapinlac H, Erasmus J, Allen-Forster K, Roth J, Putnam JB, Moran C, Cox JD. SUV by FDG-PET predicts outcome of non-small cell lung cancer. Int J Radiat Oncol Biol Phys 57 (Suppl)(2):S166, 2003.
39. Ozaki K, Yang DJ, Macapinlac HA, Yu D, Kohanim S, Kim EE, Podoloff DA. 18F-Fluoropenciclovir for PET assessment of HSV-TK reporter gene expression and localization. J Nucl Med 42(1109):274P, 2002.
40. Gayed I, Vu T, Macapinlac HA. Comparison of bone and F-18 FDG scans in the evaluation of bony metastases. J Nucl Med 43(Suppl):285P, 2002.
41. Yang DJ, Macapinlac HA, Yu D, Azhdarinia A, Kohanim S, Bryant JL, Kim EE, Podoloff DA. Glucosamine pathway imaging using 99mTc-EC-deoxyglucose in comparison with 18F-FDG. J Nucl Med 43(1478):368P, 2002.
42. Gayed I, Sureshbabu W, Iyer R, Macapinlac H Johnson M, Podoloff DA. Positron emission tomography versus computerized tomography for identification of melanoma metastases. J Nucl Med 43(1187):294P, 2002.
43. Macapinlac HA, Podoloff DA, Swanston N, Acoy D, Mawlawi O, Champagne J. Utility of FDG PET in identifying richters transformation in patients with chronic lymphocytic leukemia (CLL). J Nucl Med 43(108):30P, 2002.
44. Machac J, Zhang Z, Nunez R, Chen WT, Macapinlac HA, Larson SM. 18F Fluorodeoxyglucose uptake in human thoracic aortas assessed in vivo by positron emission tomography. J Nucl Med 42(201):54P, 2001.
45. Nehmeh SA, Ford E, Macapinlac HA, Larson SM, Mageras G, Yorke E, Humm J, Sidhu K, Pentlow K, Squire O, Yusef E. Gated positron emission tomography: A technique for reducing lung tumor motion effect. J Nucl Med 42(124):34P, 2001.
46. Erdi YE, Yorke ED, Erdi AK, Hu YC, Braban LE, Macapinlac H, Humm JL, Squire OD, Larson SM, Chui CS, Rosenzweig K. The role of PET in radiotherapy treatment planning for patients with non-small cell lung cancer (NSCLC). J Nucl Med 42(1255):302P, 2001.
47. Santiago JF, Macapinlac HA, Yeung H, Larson SM. The uptake of 18F-FDG PET scans in the management of 133 breast cancer patients. J Nucl Med 42(1236):297P, 2001.
48. Yeung HW, Erdi Y, Squire O, Macapinlac HA, Larson SM. Standardized uptake value normalized to body surface area (SUVBSA) for pediatric patients. J Nucl Med 42(815):189P, 2001.

Book Chapters

1. Rohren EM, Macapinlac HA. PET Imaging of Prostate Cancer: Other Tracers. In: PET Clinics. SAUNDERS: New York, NY, 185-192, 2009.
2. Macapinlac HA. FDG PET in Breast Cancer. In: Advanced Therapy of Breast Disease. BC Decker, 2004.
3. Macapinlac HA. The Role of PET in Planning Radiation Therapy and Monitoring It’s Effects. In: Nuclear Medicine Annual. Lippincott, Williams, & Wilkins, 163-173, 2004.
4. Abdel-Dayem HM, Scott AM, Macapinlac, HA. Thallium 201 Chloride: A Tumor Imaging Agent. In: Nuclear Medicine in Clinical Diagnosis and Treatment. Churchill Livingston, 71-81, 2004.
5. Macapinlac HA. Head and Neck Cancer. In: Principles and Practice of Positron Emission Tomography. Lippincott, Williams, & Wilkins, 2002.
6. Macapinlac HA. Hepatic Artery Pump Evaluation Prior to Locoregional Chemotherapy of Hepatic Metastases from Colorectal Cancer in Nuclear Medicine. In: test. Lippincott, Williams, and Wilkins, 2000.
7. Chisin R, Macapinlac HA. The Indications of FDG PET in Head and Neck Oncology. In: Radiol Clin North Am, 999-1012, 2000.
8. Abdel-Dayem, HM, Macapinlac, HA. Malignant Lymphoma. In: Clinical Nuclear Medicine. Thomson Science & Professional, 517- 524, 1998.
9. Abdel-Dayem, HM, Macapinlac, HA. Thallium 201 Chloride, A Tumor Imaging Agent. In: Nuclear Medicine in Clinical Diagnosis and Treatment. Churchill Livingston, 831-842, 1998.
10. Macapinlac HA. The Role of Nuclear Medicine in the Diagnosis and Treatment of Liver Metastases from Colorectal Carcinoma. In: Nuclear Medicine Annual. Lippincott-Raven Publishers, 163-179, 1997.
11. Finn, R, Macapinlac, HA, Humm, J, Pentlow, K, McDevitt, M, Tjuvajev, JBlasberg, R, Scheinberg, D, Larson, SM, Zweit, J. Application of PET radionuclides for nuclear medicine targeted therapies. In: Application of accelerators in research and industry: Proceedings of the 14th International Conference. American Institute of Physics, 1345-1347, 1996.
12. Finn, RD, Divgi, CR, Goldsmith, SJ, Larson, SM, Macapinlac, HA, Scott, AM, Yeh, SDJ. Radionuclides and their application to oncology research. In: Chemists’ views of imaging centers. Plenum Press, 277-284, 1995.
13. Abdel-Dayem, HM, Macapinlac, HA, Larson, SM, Scott, AM. Adult malignancy: thallium scintigraphy. In: Nuclear Medicine in Clinical Diagnosis and Treatment. Churchill Livingston, 727-735, 1994.
14. Abdel-Dayem, HM, Scott, AM, Macapinlac, HA, El-Gazzar, AH, Larson, SM. Role of Thallium-201 Chloride and Tc-99m Sestamibi in Tumor Imaging. In: Nuclear Medicine Annual. Raven Press, 181-234, 1994.
15. Abdel-Dayem, HM, Macapinlac HA, Larson, SM. The role of thallium chloride in brain tumor imaging. In: Brain: Diagnosis and Radionuclides, Current Status and Future Aspects. Mediterrea, 81-88, 1992.

Books (edited and written)

1. Du, Young. PET/CT in Colorectal Cancer. In: Clinicians' Guides to Radionuclide hybrid Imaging. Ed(s) Bomanji,Jamshed B.;Gnanasegaran,Gopinath;Fanti,Stefano; Macapinlac, Homer. Springer, 2017.
2. Seshadri,Nagabhushan;Eswar,Chinnamani. PET/CT in Cancer of Unknown Primary. In: Clinicians' Guides to Radionuclide Hybrid Imaging. Ed(s) Bomanji,Jamshed B.;Gnanasegaran,Gopinath;Fanti,Stefano; Macapinlac, Homer. Springer, 2017.
3. Hofman,Michael S.; Hicks,Rodney J.. PET/CT in Melanoma. In: Clinicians' Guides to Radionuclide hybrid Imaging. Ed(s) Bomanji,Jamshed B.;Gnanasegaran,Gopinath;Fanti,Stefano; Macapinlac, Homer. Springer, 2017.
4. Kayani,Irfan. PET/CT in Hodgkin's Lymphoma. In: Clinicians' Guides to Radionuclide hybrid Imaging. Ed(s) Bomanji,Jamshed B.;Gnanasegaran,Gopinath;Fanti,Stefano; Macapinlac, Homer. Springer, 2017.
5. Chua,Sue. PET/CT in Radiotherapy Planning. In: Clinicians' Guides to Radionuclide hybrid Imaging. Ed(s) Bomanji,Jamshed B.;Gnanasegaran,Gopinath;Fanti,Stefano; Macapinlac, Homer. Springer, 2017.
6. Szyszko,Teresa. PET/CT in Oesophageal and Gastric Cancer. In: Clinicians' Guides to Radionuclide Hybrid Imaging - PET/CT. Ed(s) Bomanji,Jamshed B.;Gnanasegaran,Gopinath;Fanti,Stefano; Macapinlac, Homer. Springer: Switzerland, 2016.
7. Bischof Delaloye A, Chiti A, Dondi M, Goh A, Macapinlac HA, Mariani G, Rangarajan V, Stevens G. IAEA Human Health Series No. 9. In: Appropriate Use of FDG-PET for the Management of Cancer Patients. Ed(s) Dondi M. International Atomic Energy Agency: Vienna, Austria, 2010.
8. Macapinlac HA. Nuclear Medicine in Tumor Diagnosis and Therapy, Diagnostic Section. In: Nuclear Medicine in Clinical Diagnosis and Treatment. Churchill Livingston, 2004.

Letters to the Editor

1. Macapinlac, HA, Larson, SM. Whole body PET in oncology. Oncology 7: 52-55, 1993.